A detailed history of Legal & General Group PLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 142,525 shares of IBRX stock, worth $403,345. This represents 0.0% of its overall portfolio holdings.

Number of Shares
142,525
Previous 142,525 -0.0%
Holding current value
$403,345
Previous $528,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.32 - $6.7 $1,540 - $3,108
464 Added 0.33%
142,525 $528,000
Q2 2024

Aug 14, 2024

BUY
$4.82 - $9.15 $129,730 - $246,272
26,915 Added 23.37%
142,061 $897,000
Q1 2024

May 14, 2024

SELL
$3.23 - $6.17 $17,387 - $33,213
-5,383 Reduced 4.47%
115,146 $618,000
Q4 2023

Feb 15, 2024

BUY
$1.25 - $5.21 $3,207 - $13,368
2,566 Added 2.18%
120,529 $605,000
Q3 2023

Nov 14, 2023

SELL
$1.29 - $3.1 $1,809 - $4,349
-1,403 Reduced 1.18%
117,963 $199,000
Q2 2023

Aug 14, 2023

BUY
$1.53 - $6.41 $97,673 - $409,207
63,839 Added 114.97%
119,366 $331,000
Q1 2023

May 15, 2023

BUY
$1.35 - $4.78 $14,416 - $51,045
10,679 Added 23.81%
55,527 $101,000
Q4 2022

Feb 14, 2023

SELL
$4.35 - $6.77 $4,893 - $7,616
-1,125 Reduced 2.45%
44,848 $227,000
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $14,366 - $25,308
3,936 Added 9.36%
45,973 $229,000
Q2 2022

Aug 22, 2022

BUY
$2.68 - $6.14 $26,526 - $60,773
9,898 Added 30.8%
42,037 $157,000
Q1 2022

May 16, 2022

BUY
$5.05 - $7.53 $5,873 - $8,757
1,163 Added 3.75%
32,139 $180,000
Q3 2021

Nov 15, 2021

BUY
$9.17 - $14.24 $170,149 - $264,223
18,555 Added 149.38%
30,976 $301,000
Q2 2021

Aug 12, 2021

BUY
$13.41 - $22.4 $40,203 - $67,155
2,998 Added 31.82%
12,421 $178,000
Q1 2021

May 17, 2021

BUY
$12.83 - $42.25 $120,897 - $398,121
9,423 New
9,423 $224,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.13B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.